Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Acquires 6,755 Shares of Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock in a transaction that occurred on Tuesday, June 30th. The shares were purchased at an average cost of $3.23 per share, for a total transaction of $21,818.65. Following the purchase, the insider directly owned 78,597 shares in the company, valued at $253,868.31. The trade was a 9.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ:SHPH opened at $3.40 on Thursday. The company has a 50 day moving average price of $5.93 and a two-hundred day moving average price of $10.74. The company has a market capitalization of $2.18 million, a PE ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 52 week low of $2.90 and a 52 week high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Connective Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals in the third quarter valued at approximately $357,000. Ikarian Capital LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth $124,000. Boothbay Fund Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth $37,000. Finally, Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .